179 related articles for article (PubMed ID: 27562715)
1. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
2. The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo.
Jiang Y; Meng Q; Chen B; Shen H; Yan B; Sun B
Biochem Biophys Res Commun; 2016 Sep; 478(1):293-299. PubMed ID: 27387230
[TBL] [Abstract][Full Text] [Related]
3. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
5. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
7. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
8. C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.
Zhu Y; Wang C; Zhou Y; Ma N; Zhou J
J Cell Physiol; 2018 Dec; 233(12):9437-9446. PubMed ID: 29968910
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
10. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
12. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
13. C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling.
Chen MB; Jiang Q; Liu YY; Zhang Y; He BS; Wei MX; Lu JW; Ji Y; Lu PH
Carcinogenesis; 2015 Sep; 36(9):1061-70. PubMed ID: 26116623
[TBL] [Abstract][Full Text] [Related]
14. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
15. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells.
Sawada M; Nakashima S; Banno Y; Yamakawa H; Hayashi K; Takenaka K; Nishimura Y; Sakai N; Nozawa Y
Cell Death Differ; 2000 Sep; 7(9):761-72. PubMed ID: 11042671
[TBL] [Abstract][Full Text] [Related]
16. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway.
Yu T; Chen C; Sun Y; Sun H; Li TH; Meng J; Shi X
Biochem Biophys Res Commun; 2015 Aug; 464(1):286-91. PubMed ID: 26116776
[TBL] [Abstract][Full Text] [Related]
17. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.
Shekhar TM; Green MM; Rayner DM; Miles MA; Cutts SM; Hawkins CJ
Mutat Res; 2015 Jul; 777():23-32. PubMed ID: 25916945
[TBL] [Abstract][Full Text] [Related]
19. The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Leja-Szpak A; Góralska M; Link-Lenczowski P; Czech U; Nawrot-Porąbka K; Bonior J; Jaworek J
Anticancer Agents Med Chem; 2019; 19(17):2079-2090. PubMed ID: 30987575
[TBL] [Abstract][Full Text] [Related]
20. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells.
Zhu X; Du X; Deng X; Yi H; Cui S; Liu W; Shen A; Cui Z
Biochem Biophys Res Commun; 2014 Sep; 452(1):72-8. PubMed ID: 25152399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
